Paid Alzheimer's Disease Clinical Trials
Alzheimer's clinical trials seeking participants. Access disease-modifying treatments. Compensation and travel assistance provided. Studies for early and mild AD.
Compensation
$2,500 - $6,000
Duration
52-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 55-85 years
- Diagnosis of mild cognitive impairment due to AD or mild AD dementia
- MMSE score typically between 20-28
- Positive amyloid status (PET scan or CSF biomarkers)
- Reliable study partner available for all visits
- Stable doses of AD medications (if taking) for 3+ months
Who May Not Qualify
- Non-Alzheimer dementia (vascular, Lewy body, frontotemporal)
- Moderate or severe Alzheimer disease
- MRI evidence of significant vascular disease
- History of stroke or seizures
- Major psychiatric disorder
Frequently Asked Questions
What types of Alzheimer's treatments are being studied?
+
Current trials include anti-amyloid antibodies, anti-tau therapies, neuroprotective agents, and combination approaches. Many studies focus on early-stage disease when intervention may be most beneficial.
What tests are required for screening?
+
Screening typically includes cognitive testing, brain MRI, and amyloid PET scan or lumbar puncture for biomarkers. These tests are provided at no cost.
Is a study partner required?
+
Yes, most Alzheimer's studies require a reliable study partner (spouse, family member, or caregiver) who can attend visits, provide information about daily functioning, and assist with study procedures.
Will travel assistance be provided?
+
Many Alzheimer's studies provide travel reimbursement or arrange transportation, recognizing that frequent visits can be challenging. Some studies also offer home health visits for certain assessments.